SRF, i am aware that ALT1102 was licensed in 2001... R&D was by far the longest path to walk for ALT1102 as it had a few targets moved along the way. Which is why at this now advanced stage it is very surprising that we are not a lot higher than we are because the finish line is in sight and for something that has come such a long way and will be worth so much?!!
ALT1103 is the corker and the main reason why i invested here the others are the icing on the cake...
Also, the word Antisense in the title of this thread is obviously referring to the drug type and not Antisense Therapeutics the company.... another antisense drug crossing the finish line is A VERY BIG DEAL and speaks volumes on where ANP is heading in a very short space of time - regardless of when development may have begun.
It may be unfortunate that Antisense used the drug type name as their company name if that makes for misleading thread titles read abroad...BUT, what matters most is when value becomes apparent.... Well, value has become apparent!!
Good Luck!
ANP Price at posting:
8.0¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)